The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Sept. 2, 2025 /PRNewswire/ -- September is Pulmonary Fibrosis Awareness Month, and the American Lung ...
Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...
Tony Award-winner Kecia Lewis and Kelsie Watts have joined the lineup of Broadway voices taking the stage in support of ...
2d
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung functionAUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") ...
Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...
Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...
PITTSBURGH — Hundreds of people gathered in Pittsburgh’s Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation’s annual walk. Participants walked on a one or two-mile course in support of ...
Opinion
2dOpinion
Canadian Pulmonary Fibrosis Foundation: Canadian Pulmonary Fibrosis Foundation: Oxygen Therapy Saves Lives and Health Care Dollars
Oxygen therapy is a lifeline for people living with chronic lung diseases like pulmonary fibrosis. It reduces hospitalizations and improves quality ...
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...
The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results